David W. Osborne Sells 15,000 Shares of I-Mab (NASDAQ:ARQT) Stock

I-Mab (NASDAQ:ARQT) insider David W. Osborne sold 15,000 shares of the firm’s stock in a transaction on Tuesday, September 29th. The stock was sold at an average price of $30.00, for a total value of $450,000.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

NASDAQ ARQT traded down $1.68 during trading hours on Thursday, reaching $27.62. 358,023 shares of the stock traded hands, compared to its average volume of 135,741. The stock has a 50 day simple moving average of $25.55 and a two-hundred day simple moving average of $27.87. I-Mab has a 1 year low of $17.10 and a 1 year high of $40.88. The company has a market cap of $1.05 billion and a price-to-earnings ratio of -1.21.

I-Mab (NASDAQ:ARQT) last released its quarterly earnings results on Tuesday, August 11th. The company reported ($0.94) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.84) by ($0.10). On average, equities research analysts expect that I-Mab will post -3.41 earnings per share for the current fiscal year.

ARQT has been the topic of a number of recent analyst reports. BidaskClub upgraded I-Mab from a “sell” rating to a “hold” rating in a research report on Wednesday, September 23rd. Zacks Investment Research downgraded I-Mab from a “hold” rating to a “sell” rating in a research report on Friday, August 14th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and three have issued a buy rating to the company. I-Mab currently has a consensus rating of “Hold” and a consensus price target of $41.00.

I-Mab Company Profile

Arcutis Biotherapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical cream formulation of roflumilast that is in Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis.

Recommended Story: How are capital gains distributions different for tax-deferred account?

Receive News & Ratings for I-Mab Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for I-Mab and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit